Organization (Hospital)
Instituto do Câncer do Estado de São Paulo
ClinicalTrials.gov lists Instituto do Câncer do Estado de São Paulo as lead sponsor of 91 trials. It has 91 active development programs and 38 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 7 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 9 in 2026 and about 6 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers Instituto do Câncer do Estado de São Paulo: 91 lead-sponsored trials and 1 legal-entity registration.
Disease areas (127)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Colorectal Neoplasms | 14 |
| Head and Neck Neoplasms | 13 |
| Breast Neoplasms | 12 |
| Prostatic Neoplasms | 10 |
| Rectal Neoplasms | 8 |
Showing 5 of 127 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 5 |
| 2024 | 5 |
| 2023 | 9 |
| 2022 | 4 |
| 2021 | 6 |
| 2020 | 7 |
| 2019 | 8 |
| 2018 | 3 |
| 2017 | 10 |
Showing 10 of 18 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 11 trials still running at the 2026-10-09 snapshot; 10 of 11 predicted trials reach the 36-month horizon; registered median of 28 months across 43 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (91)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Tranexamic Acid | Prostatic Neoplasms | Phase 3 | 1 |
| Encapsulated amisulpride 50 mg (matched for color, weight, smell and size) | Nausea | Phase 2 | 1 |
| Encapsulated amisulpride 50 mg (matched for color, weight, smell and size) | Vomiting | Phase 2 | 1 |
| Encapsulated amisulpride 50 mg (matched for color, weight, smell and size) | Postoperative Nausea and Vomiting | Phase 2 | 1 |
| AG/FOLFIRINOX | Stomach Neoplasms | Phase 2 | 1 |
Showing 5 of 91 active programs.
Approved assets (38)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Aprepitant | 2 |
| Oral steroid - predonisolone | 1 |
| Local steroid - triamcinolone acetonide | 1 |
| Ketorolac | 1 |
| DEXAMETHASONE | 1 |
Showing 5 of 38 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 38% hit target (n=24) | 52% on time (n=25) |
Journals published in (158)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 14 |
| European urology | 13 |
| Cancer | 9 |
| JAMA | 8 |
| Lancet (London, England) | 8 |
Showing 5 of 158 journals.
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Sao Paulo General Hospital | Co sponsors trial with | 2 |
| Hospital de Câncer de Barretos | Co sponsors trial with | 2 |
| American Society of Hematology | Co sponsors trial with | 1 |
| Universidade de São Paulo | Co sponsors trial with | 1 |
| Servier (France) | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (103)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 103 events.
Biomarker capability evidence (91)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CEACAM5 | Trial sponsor | Named in trial inclusion criteria |
| EDA | Trial sponsor | Named in trial inclusion criteria |
| ERBB2 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 91 evidence rows.
Biomarkers this organization publishes on (295)
Shown in this order: most publications first.
Showing 5 of 295 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.